Longer-Term Assessment of Azithromycin for Reducing Childhood Mortality in Africa | Zendy

Jeremy D. Keenan | Zendy; Ahmed M. Arzika | Zendy; Ramatou Maliki | Zendy; Nameywa Boubacar | Zendy; Sanoussi Elh Adamou | Zendy; Maria M Ali | Zendy; Catherine Cook | Zendy; Elodie Lebas | Zendy; Ying Lin | Zendy; Kathryn J. Ray | Zendy; Kieran S. O’Brien | Zendy; Thuy Doan | Zendy; Catherine E. Oldenburg | Zendy; E. Kelly Callahan | Zendy; Paul M. Emerson | Zendy; Travis C. Porco | Zendy; Thomas M. Lietman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Longer-Term Assessment of Azithromycin for Reducing Childhood Mortality in Africa

Author(s) -

Jeremy D. Keenan,

Ahmed M. Arzika,

Ramatou Maliki,

Nameywa Boubacar,

Sanoussi Elh Adamou,

Maria M Ali,

Catherine Cook,

Elodie Lebas,

Ying Lin,

Kathryn J. Ray,

Kieran S. O’Brien,

Thuy Doan,

Catherine E. Oldenburg,

E. Kelly Callahan,

Paul M. Emerson,

Travis C. Porco,

Thomas M. Lietman

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1817213

Subject(s) - azithromycin , medicine , placebo , confidence interval , demography , placebo group , randomized controlled trial , pediatrics , antibiotics , sociology , microbiology and biotechnology , biology , alternative medicine , pathology

The MORDOR I trial (Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance) showed that in Niger, mass administration of azithromycin twice a year for 2 years resulted in 18% lower postneonatal childhood mortality than administration of placebo. Whether this benefit could increase with each administration or wane owing to antibiotic resistance was unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research